Your session is about to expire
← Back to Search
SHP2 Inhibitor for Solid Cancers
Study Summary
This trial is testing a new drug to see what dose is tolerated by patients and what the side effects are.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My condition did not improve, or I cannot tolerate, or I refuse standard treatments.I have not had a stroke or heart attack in the last 6 months.My cancer has KRAS or EGFR mutations.I have not taken SHP2 inhibitors before.I have stable brain metastases and haven't needed steroids for 4 weeks.You have a current or past autoimmune disease that could come back.I haven't had another cancer within 3 years, or if I did, it's unlikely to return.I don't have any major side effects from cancer treatment, except for hair loss.I am 18 years or older and have agreed to participate in this study.I haven't taken high-dose steroids or immunosuppressants in the last 2 weeks.I am fully active or can carry out light work.You have at least one specific spot that can be measured to see how the treatment is working.My organs are functioning well.I can take pills and don't have major stomach or intestine issues.
- Group 1: Dose Escalation and Expansion
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is HBI-2376 a risk to the public's well-being?
"There is restricted clinical data substantiating the safety of HBI-2376, so it obtained a score of 1."
How many medical facilities are participating in this clinical research?
"This study is enrolling participants at Providence Medical Foundation in Fullerton, Florida; City of Hope in Duarte, Ohio; and California Cancer Associates for Research and Excellence (cCare) Inc. in Encinitas, Texas as well as 11 other medical sites."
Are new participants being accepted for this clinical trial?
"Clinicaltrials.gov confirms that this clinical trial is currently looking for participants to join, with the initial post made on December 13th 2021 and the most recent edit being August 23rd 2022."
How many people have enrolled in this research endeavor?
"Affirmative. As observed on clinicaltrials.gov, this medical trial is actively recruiting participants with an initial posting date of December 13th 2021 and a last update occurring August 23rd 2022. Altogether there are 11 different sites looking to enrol 42 individuals in the study."
Share this study with friends
Copy Link
Messenger